The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

St. Jude marathon raises $10 million

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ST. JUDE MEMPHIS MARATHON WEEKEND Dec. 3 raised $10 million for St. Jude Children’s Research Hospital.

Over the past 15 years, participants running as St. Jude Heroes have joined the fight against childhood cancer and raised more than $60 million to support St. Jude.

About 23,000 people took part in the race that drew 40,000 spectators.

Unique to this event is the race route through the St. Jude campus where patient families cheer from the sidelines to remind walkers and runners they are running for a greater purpose—to help ensure families never receive a bill from St. Jude for treatment, travel, housing or food.

The marathon weekend is a collaborative effort between ALSAC/St. Jude Children’s Research Hospital and the Memphis Runners Track Club.

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

What happened at FDA? Replimune approval raises questions

Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
Regulatory News

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

FDA has granted an accelerated approval to RP1 (vusolimogene oderparepvec) following the agency’s Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
By Jacquelyn Cobb and Paul Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account